Cited by 8Fatty Acid Research and HealthHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Association of plasma omega-3 levels with incident heart failure and related mortalities

Open access
Jawad, Mohammad Abdel, O’Keefe, James H., Tintle, Nathan, O’Keefe, Evan L., Franco, W. Grant, Djousse, Luc, Ryder, Nathan, Harris, William S.·2024·Mayo Clinic Proceedings

Abstract

Objective To investigate the association between plasma omega-3 levels and incident heart failure (HF) and to examine their relationship with total and cardiovascular (CV) mortality among patients with preexisting HF. Patients and methods The UK Biobank is an ongoing prospective cohort study of individuals recruited in the United Kingdom between April 1, 2007, and December 31. 2010. We used Cox proportional hazards models to predict incident HF in those without baseline HF and total and CV mortality in those with baseline HF, all as a function of baseline plasma omega-3 levels. Results In participants without HF at baseline (n=271,794), a generally linear inverse association was observed between omega-3 levels and incident HF during a median follow-up of 13.7 years. The risk was 21% lower in the highest quintile of omega-3 compared with the lowest quintile (hazard ratio, 0.79; 95% CI, 0.74 to 0.84; P<.001) in multivariable models. In parallel models in participants with prevalent HF (n=1239), risk for all-cause and CV mortality were both reduced by approximately 50% comparing top to bottom omega-3 quintiles (hazard ratio, 0.53; 95% CI, 0.33 to 0.86; and hazard ratio, 0.50; 95% CI, 0.31 to 0.79, respectively; both P<.01). Conclusion Higher plasma levels of marine omega-3 fatty acids were associated with a lower incidence of HF. Furthermore, among patients with preexisting HF, higher omega-3 levels were associated with lower risks of all-cause mortality and CV mortality. These findings suggest that increasing plasma omega-3 levels, whether by diet or supplementation, could reduce both risk for development of HF and death in those with prevalent HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2024.08.007

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher levels of omega-3 biomarkers are associated with lower risk for ASCVD, Alzheimer's disease, total dementia, heart failure, diabetes, suicidal ideation/self-harm, poor lung function, colorectal cancer, several other malignancies, atopic dermatitis, hospitalization for sepsis, liver cirrhosis, chronic kidney disease, frailty, and hip fractures.

    “Other biomarker-based studies have found higher levels of omega-3s to be associated with lower risk for ASCVD116, Alzheimer’s disease130 and total dementia130, heart failure131, diabetes132, suicidal ideation/self-harm133, poor lung function134, colorectal cancer135 and several other malignancies136, atopic dermatitis137, hospitalization for sepsis138, liver cirrhosis139, chronic kidney disease140”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. [1]Abovich A, Matasic DS, Cardoso R, The AHA/ACC/HFSA 2022 heart failure guidelines: changing the focus to heart failure prevention. Am J Prev Cardiol. 2023; 15: 100527. 37637197 PMC10457686
  2. [2]Heidenreich PA, Bozkurt B, Aguilar D, 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary; a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18): e876– e894. 35363500
  3. [3]Zhu Z, Li F-R, Jia Y, Association of lifestyle with incidence of heart failure according to metabolic and genetic risk status: a population-based prospective study. Circ Heart Fail. 2022; 15(9): e009592. 35975661
  4. [4]Lichtenstein AH, Appel LJ, Vadiveloo M, 2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021; 144(23): e472– e487. 34724806
  5. [5]Rimm EB, Appel LJ, Chiuve SE,; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2018; 138(1): e35– e47. 29773586 PMC6903778
  6. [6]Djoussé L, Cook NR, Kim E, Diabetes mellitus, race, and effects of omega-3 fatty acids on incidence of heart failure hospitalization. JACC Heart Fail. 2022; 10(4): 227– 234. 35361440 PMC8986092
  7. [7]O’Keefe JH, O’Keefe EL, Lavie CJ. Omega-3: the overlooked evidence-based therapy for heart failure [editorial]. JACC Heart Fail. 2022; 10(4): 235– 237 35361441
  8. [8]Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS. Fish intake and risk of incident heart failure. J Am Coll Cardiol. 2005; 45(12) 2015– 2021. 15963403
  9. [9]Zheng S, Qiu M, Wu JHY, Long-chain omega-3 polyunsaturated fatty acids and the risk of heart failure. Ther Adv Chronic Dis. 2022; 13. 20406223221081616. PMC8935400 35321400
  10. [10]Block RC, Liu L, Herrington DM, Predicting risk for incident heart failure with omega-3 fatty acids: from MESA. JACC Heart Fail. 2019; 7(8): 651– 661. 31302044 PMC12442024
  11. [11]O’Connell TD, Block RC, Huang SP, Shearer GC. ω3-Polyunsaturated fatty acids for heart failure: effects of dose on efficacy and novel signaling through free fatty acid receptor 4. J Mol Cell Cardiol. 2017; 103: 74– 92. 27986444 PMC5944298
  12. [12]Mozaffarian D, Lemaitre RN, King IB, Circulating long-chain u-3 fatty acids and incidence of congestive heart failure in older adults: the Cardiovascular Health Study; a cohort study. Ann Intern Med. 2011; 155(3): 160– 170. 21810709 PMC3371768
  13. [13]Dijkstra SC, Brouwer IA, van Rooij FJA, Hofman A, Witteman JCM, Geleijnse JM. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail. 2009; 11(10): 922– 928. 19789394
  14. [14]Wilk JB, Tsai MY, Hanson NQ, Gaziano JM, Djoussé L. Plasma and dietary omega-3 fatty acids, fish intake, and heart failure risk in the Physicians’ Health Study. Am J Clin Nutr. 2012; 96(4): 882– 888. 22952185 PMC3441114
  15. [15]Tavazzi L, Maggioni AP, Marchioli R,; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9645): 1223– 1230. 18757090
  16. [16]Sudlow C, Gallacher J, Allen N, UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015; 12(3): e1001779. 25826379 PMC4380465
  17. [17]Julkunen H, Cichońska A, Tiainen M, Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. Nat Commun. 2023; 14(1): 604. 36737450 PMC9898515
  18. [18]Schuchardt JP, Cerrato M, Ceseri M, Red blood cell fatty acid patterns from 7 countries: focus on the Omega-3 Index. Prostaglandins Leukot Essent Fatty Acids. 2022; 179: 102418. 35366625 PMC10440636
  19. [19]Chao T, Sun J, Ge Y, Wang C. Effect of omega-3 fatty acids supplementation on the prognosis of coronary artery disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2024; 34(3): 537– 547. 38161115
  20. [20]Djoussé L, Cook NR, Kim E, Supplementation with vitamin D and omega-3 fatty acids and incidence of heart failure hospitalization: VITAL-Heart Failure. Circulation. 2020; 141(9): 784– 786. 31709816 PMC7054158
  21. [21]Manson JE, Cook NR, Lee I-M, VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019; 380(1): 33– 44. 30415629 PMC6425757
  22. [22]Masson S, Marchioli R, Mozaffarian D, Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. Am Heart J. 2013; 165(2): 208– 215.e4. 23351824
  23. [23]Garaiova I, Guschina IA, Plummer SF, Tang J, Wang D, Plummer NT. A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification. Nutr J. 2007; 6: 4. 17254329 PMC1796891
  24. [24]Raatz SK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM. Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil. J Am Diet Assoc. 2009; 109(6): 1076– 1081. 19465191 PMC2701654
  25. [25]Liao J, Xiong Q, Yin Y, Ling Z, Chen S. The effects of fish oil on cardiovascular diseases: systematical evaluation and recent advance. Front Cardiovasc Med. 2022; 8: 802306. 35071366 PMC8767101
  26. [26]Li K, Huang T, Zheng J, Wu K, Li D. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: a meta-analysis. PLoS One. 2014; 9(2): e88103. 24505395 PMC3914936
  27. [27]Li L-Y, Wang X, Zhang T-C, Liu Z-J, Gao J-Q. Cardioprotective effects of omega 3 fatty acids from fish oil and it enhances autoimmunity in porcine cardiac myosin-induced myocarditis in the rat model. Z Naturforsch C J Biosci. 2021; 76(9-10): 407– 415. 34049426
  28. [28]Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006; 16(5): 141– 146. 16781946 PMC2749293
  29. [29]Itoh M, Suganami T, Satoh N, Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007; 27(9): 1918– 1925. 17569885
  30. [30]Oppedisano F, Mollace R, Tavernese A, PUFA supplementation and heart failure: effects on fibrosis and cardiac remodeling. Nutrients. 2021; 13(9): 2965. 34578843 PMC8471017
  31. [31]Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021; 128(10): 1421– 1434. 33983838
  32. [32]Niazi ZR, Silva GC, Ribeiro TP, EPA:DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase- and COX-derived oxidative stress. Hypertens Res. 2017; 40(12): 966– 975. 28878301
  33. [33]Fry A, Littlejohns TJ, Sudlow C, Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017; 186(9): 1026– 1034. 28641372 PMC5860371

Cited by

Sorted by citations

Authors
Jawad, M. A., O’Keefe, J. H., Tintle, N., O’Keefe, E. L., Franco, W. G., Djousse, L., Ryder, N., & Harris, W. S.
Affiliations
  • Saint Luke's Hospital (US)
  • University of Illinois Chicago (US)
  • Fatty Acid Research Institute (US)
  • University of South Dakota (US)
Corresponding author
O’Keefe, James H.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2024-12
Volume
99
Issue
12
Pages
1895-1904
ISSN
0025-6196 (ISSN-L)
OpenAlex
W4404933586
Cited by
8
References
1
Citations by year
2026: 3 · 2025: 4 · 2024: 1
FWCI
2.14
Type
journal article
Language
en
Open access
Locations
  • Mayo Clinic Proceedings (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, other-oa)
Funders
National Heart, Lung, and Blood Institute
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
omega-3 fatty acids, heart failure, incident heart failure, cardiovascular mortality, all-cause mortality, omega-3 supplementation, UK Biobank
MeSH terms
Adult, Aged, Female, United Kingdom, Heart Failure, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Biomarkers, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review